OverviewSuggest Edit

Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

TypePublic
Founded2008
HQPhiladelphia, PA, US
Websiteadaptimmune.com
Employee Ratings3.8

Latest Updates

Employees (est.) (Dec 2019)400(-6%)
Job Openings62
Revenue (FY, 2020)$4 M(+253%)
Share Price (Sept 2021)$6.2
Cybersecurity ratingBMore

Key People/Management at Adaptimmune

David M. Mott

David M. Mott

Chairman
Gavin Wood

Gavin Wood

Chief Financial Officer
Lawrence M. Alleva

Lawrence M. Alleva

Non-Executive Director
Mark Dudley

Mark Dudley

Senior Vice President, Early Stage Development
Helen Tayton-Martin

Helen Tayton-Martin

Chief Business Officer
Ali Behbahani

Ali Behbahani

Non-Executive Director
Show more

Adaptimmune Office Locations

Adaptimmune has offices in Philadelphia, Milton and Stevenage
Philadelphia, PA, US (HQ)
351 Rouse Blvd
Milton, GB
101 Park Dr
Milton, GB
60 Jubilee Ave
Stevenage, GB
Gunnels Wood Rd
Show all (4)

Adaptimmune Financials and Metrics

Adaptimmune Revenue

Adaptimmune's revenue was reported to be $3.96 m in FY, 2020
USD

Revenue (Q1, 2021)

434.0k

Net income (Q1, 2021)

(37.8m)

EBIT (Q1, 2021)

(37.9m)

Market capitalization (9-Sept-2021)

965.6m

Closing stock price (9-Sept-2021)

6.2

Cash (31-Mar-2021)

32.4m

EV

955.9m
Adaptimmune's current market capitalization is $965.6 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

14.2m37.8m59.5m1.1m4.0m

EBIT

(72.8m)(80.7m)(82.4m)(139.8m)(133.4m)

EBIT margin, %

(513%)(213%)(138%)(12457%)(3371%)

Interest expense

1.1m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

2.9m328.0k2.4m2.9m3.5m27.2m8.2m9.0m40.8m157.0k237.0k761.0k502.0k1.2m434.0k

General and administrative expense

11.8m10.1m9.3m10.3m13.0m13.8m

R&D expense

22.0m25.5m21.3m20.5m24.1m24.5m

Operating expense total

33.8m35.7m30.5m30.8m37.1m38.3m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

158.8m84.0m68.4m50.4m56.9m

Accounts Receivable

149.5k206.0k192.0k139.0k

Prepaid Expenses

21.7m25.8m30.9m29.8m

Inventories

1.4m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(23.0m)(70.1m)(95.5m)(137.2m)(130.1m)

Depreciation and Amortization

5.4m7.8m8.0m7.6m

Accounts Payable

3.9m

Cash From Operating Activities

(48.2m)(54.3m)(104.4m)(112.5m)(53.6m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(15.6m)(37.7m)(56.2m)(21.8m)(42.0m)(42.9m)(21.1m)(64.6m)(59.3m)(27.4m)(68.5m)(107.8m)(28.2m)(58.0m)(93.5m)(37.8m)

Depreciation and Amortization

707.0k1.5m2.3m1.0m2.2m3.7m1.9m3.8m5.7m2.0m4.0m5.9m1.7m3.6m5.2m1.4m

Accounts Payable

(2.7m)3.6m(117.0k)(8.6m)

Cash From Operating Activities

(18.7m)(35.2m)(50.5m)(28.4m)(46.4m)(33.0m)(47.3m)(82.6m)(72.7m)(36.2m)(70.4m)(100.0m)16.9m(8.1m)(24.4m)(46.5m)
USDQ1, 2016

Financial Leverage

1.2 x
Show all financial metrics

Adaptimmune Operating Metrics

FY, 2016

Patent Applications

69

Patents Issued

173
Show all operating metrics

Adaptimmune Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

SecurityScorecard logo

Adaptimmune Online and Social Media Presence

Embed Graph

Adaptimmune News and Updates

Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies

- Combining both companies’ cell therapy leadership and expertise, the collaboration covers the research and development of “off-the-shelf” cell therapies for up to five shared cancer targets and the development of a novel allogeneic personalized cell therapy platform -

Adaptimmune Updates Data from its Phase 1 Trial for Liver Cancer at ILCA Showing Clinical Benefit

- One complete response, and a disease control rate of 64% with stable disease for ≥16 weeks in two patients, as of the data cutoff -

Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 28, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the second quarter ended June 30, 2021, after the US markets close o…

Thinking about buying stock in Oncternal Therapeutics, Polarityte, Adaptimmune Therapeutics, Oncolytics Biotech, or Precipio?

NEW YORK, May 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONCT, PTE, ADAP, ONCY, and PRPO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Adaptimmune Reports First Quarter Financial Results and Business Update

- Initial SPEARHEAD-1 data to be presented in an oral presentation at ASCO -

Adaptimmune to Report Q1 2021 Financial Results and Business Update on Thursday, May 6, 2021

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 22, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the first quarter ended March 31, 2021, before the US markets open …
Show more

Adaptimmune Blogs

Adaptimmune Reports Second Quarter Financial Results and Business Update

- SPEARHEAD-1 data presented at ASCO with overall response rate of 39.3% in synovial sarcoma and MRCLS; on track to file BLA for afami-cel next year - - SURPASS trial data from 23 evaluable patients to be presented at ESMO - - ADP-A2AFP Phase 1 trial data from 11 evaluable patients in Group 3/Expa…

Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in Adaptimmune’s Phase 2 SPEARHEAD-1 Trial

- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 19, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc…

Adaptimmune to Present First Preclinical Data from its HLA-independent TCR (HiT) Platform at ASGCT

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial preclinical data from its HLA Independent TCR (HiT) targeting mesothelin, being co-developed with Astellas, dur…

Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC

- Data support continued development of ADP-A2M4CD8 - - On track to start Phase 2 trial in gastroesophageal cancers in the first half of 2021 - PHILADELPHIA, Pa. and OXFORDSHIRE, UK., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in cell therapy to treat…

Adaptimmune Reports Q3 Financial Results and Business Update

- Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients - - Safety and response data from dose escalation cohorts of the SURPASS trial to be presented at SITC - - Durability of response data from patients with …

Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial

PHILADELPHIA and OXFORDSHIRE, United Kingdom, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”) (Nasdaq: ADAP), a leader in cell therapy to treat cancer is aware of the early release of the abstract entitled “Initial safety, efficacy, and product attributes from the SU…
Show more

Adaptimmune Frequently Asked Questions

  • When was Adaptimmune founded?

    Adaptimmune was founded in 2008.

  • Who are Adaptimmune key executives?

    Adaptimmune's key executives are David M. Mott, Gavin Wood and Lawrence M. Alleva.

  • How many employees does Adaptimmune have?

    Adaptimmune has 400 employees.

  • What is Adaptimmune revenue?

    Latest Adaptimmune annual revenue is $4 m.

  • What is Adaptimmune revenue per employee?

    Latest Adaptimmune revenue per employee is $9.9 k.

  • Who are Adaptimmune competitors?

    Competitors of Adaptimmune include Bellicum Pharmaceuticals, TCR2 Therapeutics and Novavax.

  • Where is Adaptimmune headquarters?

    Adaptimmune headquarters is located at 351 Rouse Blvd, Philadelphia.

  • Where are Adaptimmune offices?

    Adaptimmune has offices in Philadelphia, Milton and Stevenage.

  • How many offices does Adaptimmune have?

    Adaptimmune has 4 offices.